Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neurobiol Dis. 2009 Oct;36(1):223-31. doi: 10.1016/j.nbd.2009.07.018. Epub 2009 Jul 25.

Pyruvate protects against experimental stroke via an anti-inflammatory mechanism.

Author information

  • 1Department of Neurology, University of California, San Francisco and Veterans Affairs Medical Center, CA 94121, USA.

Abstract

Pyruvate, a key intermediate in glucose metabolism, was explored as a potential treatment in models of experimental stroke and inflammation. Pyruvate was administered to rodents after the onset of middle cerebral artery occlusion (MCAO). Since the extent of inflammation is often proportional to the size of the infarct, we also studied a group of animals given lipopolysaccharide (LPS) to cause brain inflammation without cell death. Following MCAO, pyruvate did not affect physiological parameters but significantly reduced infarct volume, improved behavioral tests and reduced numbers of neutrophils, microglial and NFkappaB activation. Animals given LPS showed increased microglial and NFkappaB activation which was almost completely abolished by pyruvate. Lactate, a major metabolite of pyruvate, was increased after pyruvate administration. However, administration of lactate itself did not have any anti-inflammatory effects. Pyruvate protects against ischemia possibly by blocking inflammation, but lactate itself does not appear to explain pyruvate's anti-inflammatory properties.

PMID:
19635562
[PubMed - indexed for MEDLINE]
PMCID:
PMC2742567
Free PMC Article

Publication Types, MeSH Terms, Substances, Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk